Analysts Defend Merck Amid Investor Concerns Over Weak Guidance

Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a lower-than-expected 2025 outlook.

Latest Ratings for MRK

Date Firm Action From To
Feb 2022 SVB Leerink Maintains Outperform
Jan 2022 JP Morgan Maintains Overweight
Dec 2021 Daiwa Capital Initiates Coverage On Neutral

View More Analyst Ratings for MRK

View the Latest Analyst Ratings

read more

Leave a Reply

Your email address will not be published. Required fields are marked *